Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2015-06-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
第六届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 普洛药业股份有限公司 regarding various internal governance matters such as approval of related party transactions, contract signings, and revisions to management systems. It includes voting results and mentions that some proposals require shareholder meeting approval. The document is dated June 8, 2015, and is relatively short (872 characters). It does not contain financial statements, audit opinions, or detailed financial data. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a notice of dividend, capital change, or shareholding change. It is a formal announcement of board-level decisions and governance-related resolutions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2015-06-08 Chinese
董事会关于公司子公司与中国科学院上海药物研究所合作开发新药的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of 普洛药业股份有限公司 regarding a cooperation agreement between its subsidiary and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, for the development of new drugs. It details the terms of the collaboration, funding milestones, intellectual property rights, and risk warnings. There are no financial statements, quarterly or annual results, or audit information presented. The document is a formal announcement of a business cooperation and strategic development, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a management change, voting result, or capital update. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2015-06-08 Chinese
西南证券股份有限公司关于公司2015年度新增关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Southwest Securities Co., Ltd. regarding the 2015 new related-party transactions of Puluo Pharmaceutical Co., Ltd. It includes descriptions of the related-party transactions, parties involved, pricing principles, approval procedures, independent directors' opinions, and the sponsor's verification conclusion. The document is focused on the audit and verification of specific related-party transactions for the year 2015, referencing regulatory requirements and internal approvals. It does not contain full financial statements or comprehensive annual or interim financial reports. It is a standalone audit-related verification report concerning related-party transactions, which fits the category of Audit Report / Information (AR). The document length is 3250 characters, which is relatively short but contains substantive audit verification content rather than just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2015
2015-06-08 Chinese
独立董事关于新增关联交易的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 普洛药业股份有限公司 regarding new related-party transactions in 2015. It references governance guidelines and the company's articles of association, and it provides an independent directors' statement on the fairness and legality of the transactions. The document is short (505 characters) and does not contain financial statements or detailed financial data. It is a governance-related statement rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board matters and management opinions.
2015-06-08 Chinese
独立董事关于对2015新增关联交易事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of new related party transactions for the year 2015. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules, and mentions that the matter will be submitted to the shareholders' meeting for approval. The document is short (469 characters) and does not contain financial statements or detailed financial data. It is a governance-related announcement concerning board opinions on related party transactions, not a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG) as it relates to board-level decisions and disclosures about governance matters.
2015-06-08 Chinese
关于规范与关联方资金往来的管理制度（2015年6月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '关于规范与关联方资金往来的管理制度' which translates to 'Management System for Regulating Funds Transactions with Related Parties'. It outlines rules and procedures for managing financial transactions between the company and its controlling shareholders and related parties, including legal responsibilities and audit requirements. There is no indication that this is a financial report, audit report, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for corporate governance and compliance with laws and regulations. Therefore, it fits best under Governance Information (CGR). The document length is 1744 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2015-06-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.